Abstract
AbstractIn the rapidly evolving landscape of biotechnologies, cell and gene therapies are being developed and adopted at an unprecedented pace. However, their access and adoption remain limited, particularly in low- and middle-income countries (LMICs). This study aims to address this critical gap by exploring the potential of applying a hub and spoke model for cell and gene therapy delivery in LMICs. We establish the identity and roles of relevant stakeholders, propose a hub and spoke model for cell and gene therapy delivery, and simulate its application in Brazil and the Middle East and North Africa. The development and simulation of this model were informed by a comprehensive review of academic articles, grey literature, relevant websites, and publicly available data sets. The proposed hub and spoke model is expected to expand availability of and access to cell and gene therapy in LMICs and presents a comprehensive framework for the roles of core stakeholders, laying the groundwork for more equitable access to these lifesaving therapies. More research is needed to explore the practical adoption and implications of this model.
Funder
Novartis Gene Therapies, Inc.
Publisher
Springer Science and Business Media LLC
Subject
Genetics,Molecular Biology,Molecular Medicine
Reference83 articles.
1. American Society of Gene & Cell Therapy (ASGCT). American Society of Gene & Cell Therapy home page. 2023. https://asgct.org. Accessed 3 April 2023.
2. U.S. National Library of Medicine. ClinicalTrials.gov home page. 2023. https://clinicaltrials.gov. Accessed 3 April 2023.
3. Kemler S, Lohr A. Cell & gene therapy investment outlook in 2022 & beyond. 2022. https://www.cellandgene.com/doc/cell-gene-therapies-investment-outlook-in-beyond-0001. Accessed 3 April 2023.
4. Quinn C, Young C, Thomas J, Trusheim M. Estimating the clinical pipeline of cell and gene therapies and their potential economic impact on the US healthcare system. Value Health 2019;22:621–6.
5. Elverum K, Whitman M. Delivering cellular and gene therapies to patients: solutions for realizing the potential of the next generation of medicine. Gene Ther. 2020;27:537–44.